Flavonoids as Natural Therapeutics for Metabolic Syndrome: Targeting Inflammation, Obesity, and Diabetes

Metabolic syndrome (MetS) is a multifactorial disorder characterized by a cluster of metabolic abnormalities, including central obesity, insulin resistance, dyslipidemia, and hypertension. These interrelated conditions significantly elevate the risk of type 2 diabetes mellitus (T2DM), cardiovascular diseases, and other chronic disorders. Inflammation and oxidative stress are now recognized as pivotal mechanisms underlying the pathogenesis of MetS. Flavonoids, a diverse class of polyphenolic compounds found abundantly in fruits, vegetables, tea, and other plant-derived products, have garnered considerable attention for their broad-spectrum biological activities. This review provides an in-depth analysis of the current evidence supporting the therapeutic potential of flavonoids in managing MetS, focusing on their anti-inflammatory, anti-obesity, and antidiabetic mechanisms. We highlight the molecular pathways modulated by flavonoids, including AMP-activated protein kinase (AMPK), nuclear factor-kappa B (NF-κB), phosphoinositide 3-kinase (PI3K)/Akt, and peroxisome proliferator-activated receptors (PPARs). Additionally, we discuss human clinical trials, bioavailability challenges, and future prospects for flavonoid-based interventions in metabolic health. Keywords: Flavonoids; Metabolic syndrome; Inflammation; Obesity; Diabetes; AMPK; Oxidative stress; Natural therapeutics; Polyphenols; Insulin resistance